{"disease":{"id":"cll-chronic-lymphocytic-leukemia","name":"cll chronic lymphocytic leukemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00923507","title":"Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT07342478","title":"ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":306,"lead_sponsor_name":"Newave Pharmaceutical Inc","has_results":false},{"nct_id":"NCT06846671","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"BeOne Medicines","has_results":false},{"nct_id":"NCT01500733","title":"PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":86,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":true},{"nct_id":"NCT07487428","title":"CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLL","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Technical University of Munich","has_results":false},{"nct_id":"NCT01517035","title":"Improving Blood Stem Cell Collection and Transplant Procedures","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT06978088","title":"LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":34,"lead_sponsor_name":"Zulfa Omer","has_results":false},{"nct_id":"NCT01145209","title":"Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":true},{"nct_id":"NCT07108998","title":"Study of Epcoritamab as a Consolidation Therapy in CLL/SLL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"Zulfa Omer","has_results":false},{"nct_id":"NCT03524235","title":"Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Noah Merin","has_results":false},{"nct_id":"NCT01117142","title":"A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT05589896","title":"A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Ossium Health, Inc.","has_results":false},{"nct_id":"NCT04694560","title":"A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03639324","title":"Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Virginia Commonwealth University","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}